Search Back New search Go to resultsDiseaseMain groupHematologic NeoplasmsProtocol groupMyeloproliferative neoplasms (MPN) and myelodysplastic neoplasms (MDS)DiseaseChronic Myeloid LeukemiaSubgroupalso in pregnancyBCR-ABL negativePh/BCR-ABL+ICD10C92.1-MeSHLeukemia, Myelogenous, Chronic, BCR-ABL PositiveLeukemia, Myeloid, Chronic, Atypical, BCR-ABL NegativeLeukemia, Myeloid, Chronic-PhaseSequenceChemotherapyChemo-substanceAsciminibBosutinibDasatinibImatinibInterferon alpha-2aInterferon alpha-2a pegylatedNilotinibPonatinibRuxolitinibChemo-substanceAsciminibBosutinibDasatinibImatinibInterferon alpha-2aInterferon alpha-2a pegylatedNilotinibPonatinibRuxolitinibChemo-substanceAsciminibBosutinibDasatinibImatinibInterferon alpha-2aInterferon alpha-2a pegylatedNilotinibPonatinibRuxolitinibChemo-substanceAsciminibBosutinibDasatinibImatinibInterferon alpha-2aInterferon alpha-2a pegylatedNilotinibPonatinibRuxolitinibNo. Substances12 RadiotherapySupportive therapySupportive substanceDexamethasoneGranisetronSupportive substanceDexamethasoneGranisetronSupportive substanceDexamethasoneGranisetronSupportive substanceDexamethasoneGranisetronNo. Substances2Protocol classificationTherapy classificationalternativecurrent standardIntensityStandard doseTherapy indicationFirst lineSecond lineseveral possibleThird line Therapy phaseTherapy intentiondisease controlRisksAlopeciaAnemia Hb below 8g/dlArthalgiaBleedingCardiotoxicityDiarrheaEdemaEmetogenicityEmetogenicity (ASCO)Emetogenicity (MASCC/ESMO)FatigueFebrile NeutropeniaHeadacheHeart FailureHemorrhageHyperglycemiaHypertensionHypophosphatemiaIncrease AminotransferasesIncrease in lipaseInfectionsLymphopeniaNeutropeniaPainPleural EffusionPneumoniaPyrexiaQTc Time ExtensionRashThrombocytopenia below 50 000/µlThromboembolic EventUpper Respiratory Tract Infection only studiesPublicationAuthorCortes JDao KTKantarjian JMubarak AO´Brien SPreudhomme CRéa DSaglio GDiseaseAtypische chronische myeloische Leukämie, BCR-ABL-negativchronisch myeloische Leukämie, Ph+/BCR-ABL+, Drittlinie und höherCML, chronische Phase, Erstlinie, ECOG 0-2CML in der SchwangeschaftCML oder Ph+/BCR+ ALL, resistent auf Dasatinib oder Nilotinib, ECOG 0-2neudiagnostizierte, Ph+/BCR-ABL+, chronische myeloische Leukämie, chronische Phase < 15% Blasten, < 20% basophile Granulozyten, ECOG 0-2neudiagnostizierte, Ph+/BCR-ABL+, chronisch myeloische Leukämie, ECOG 0-1neudiagnostizierte, Ph+ chronische myeloische Leukämie, ECOG 0-2Ph+/BCR-ABL+ chronische myeloische Leukämie, chronische Phase < 15% Blasten, < 20% basophile GranulozytenOriginDepartment of Leukemia, University of Texas M.D. Anderson Cancer Center, Houston, PACE trialDMU Hématologie, Hôpital Saint-Louis, Paris, France, ASCEMBL trialHamad Medical Corporation, Hematology/Oncology Division, Doha, QatarKnight Cancer Institute, Oregon Health and Science University, Portland, USALaboratoire d’Hématologie, Centre Hospitalier Universitaire, Lille, SPIRIT trialThe University of Texas MD Anderson Cancer Center, Houston, TX, BELA trialUniversity of Newcastle, Newcastle, United Kingdom, IRIS InvestigatorsUniversity of Texas M.D. Anderson Cancer Center, Houston, DASISION trialUniversity of Turin, San Luigi Gonzaga Hospital, Orbassano, Turin, Italy, ENESTnd InvestigatorsProtocols in Revision 9 protocols foundProtocols under revision.Asciminib 40, Chronic Myeloid Leukemia (PID2144 V1.0)Bosutinib 500, Chronic Myeloid Leukemia (PID946 V1.1)Dasatinib 100, Chronic Myeloid Leukemia (PID940 V1.0)Imatinib 400 / peginterferon alpha-2a 90, Chronic Myeloid Leukemia, Chronic Phase (PID952 V1.1)Imatinib 400, Chronic Myeloid Leukemia (PID934 V1.1)Interferon Alpha-2a 3 million, Chronic Myeloid Leukemia (PID951 V1.0)Nilotinib 300, Chronic Myeloid Leukemia, Chronic Phase (PID938 V1.1)Ponatinib 45, Chronic Myeloid Leukemia (PID950 V1.0)Ruxolitinib 15, Chronic Myeloid Leukemia, atypical (PID1649 V1.0)
